Clinical Characteristics and Treatment Patterns of Pityriasis Rubra Pilaris: A Canadian Retrospective Study
- PMID: 39323064
- DOI: 10.1177/12034754241287553
Clinical Characteristics and Treatment Patterns of Pityriasis Rubra Pilaris: A Canadian Retrospective Study
Keywords: biologic; papulosquamous; pityriasis rubra pilaris; retrospective study; treatment.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MAH received honorariums, served as a speaker and/or advisor for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Janssen, Leo, Lilly, L’Oreal, Medexus, Novartis, Pfizer, Sanofi, Sun Pharma. AC has served on advisory boards, received honourariums, or contributed to clinical trials for AbbVie, Amgen, Aralez Pharmaceuticals, Bausch Health, Celgene Corporation, Eli Lilly, Galderma, Janssen, Johnson and Johnson, LEO Pharma, Novartis, Pfizer, Sanofi, UCB, and Valeant. MG has served as investigator/consultant or speaker for AbbVie, Akros Pharma, Amgen, Arcutis Biotherapeutics, Aslan, Aristea, Anaptys-Bio, Bausch, BMS, Boehringer Ingelheim, Coherus BioSciences, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, Inmagene, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron Pharmaceuticals, Reistone, Roche, Sanofi, Sun Pharma, Takeda, Tarsus, Union, UCB, and Ventyx. AO received honourariums, served as a speaker, and/or advisor, or contributed to clinical trials for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma, Amgen, Bausch Health, UCB, Incyte, Moonlake, Nimbus, and Ventyx. MB and IS have no conflict of interest to declare. No conflicts of interest affected the study’s validity/outcome.
Publication types
LinkOut - more resources
Full Text Sources
